The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response
about
Unanchored K48-linked polyubiquitin synthesized by the E3-ubiquitin ligase TRIM6 stimulates the interferon-IKKε kinase-mediated antiviral responseOptineurin negatively regulates the induction of IFNbeta in response to RNA virus infectionImmune signaling by RIG-I-like receptorsAnkrd17 positively regulates RIG-I-like receptor (RLR)-mediated immune signalingA novel function of human Pumilio proteins in cytoplasmic sensing of viral infectionReconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunityZAPS is a potent stimulator of signaling mediated by the RNA helicase RIG-I during antiviral responsescIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoformsREUL is a novel E3 ubiquitin ligase and stimulator of retinoic-acid-inducible gene-IMDA5 is SUMOylated by PIAS2β in the upregulation of type I interferon signalingMitochondrially localised MUL1 is a novel modulator of antiviral signalingMapping a dynamic innate immunity protein interaction network regulating type I interferon productionFunction and regulation of retinoic acid-inducible gene-IUbiquitin signaling in immune responsesUbiquitin in the activation and attenuation of innate antiviral immunityThe two faces of receptor interacting protein kinase-1Ubiquitin in the immune systemNegative regulation of cytoplasmic RNA-mediated antiviral signalingStructure and Dynamics of the Second CARD of Human RIG-I Provide Mechanistic Insights into Regulation of RIG-I ActivationRIG-I-like receptor regulation in virus infection and immunityLGP2 synergy with MDA5 in RLR-mediated RNA recognition and antiviral signalingNegative regulation of RIG-I-mediated innate antiviral signaling by SEC14L1Key role of Ubc5 and lysine-63 polyubiquitination in viral activation of IRF3Negative regulation of interferon-β gene expression during acute and persistent virus infectionsFLN29 deficiency reveals its negative regulatory role in the Toll-like receptor (TLR) and retinoic acid-inducible gene I (RIG-I)-like helicase signaling pathwayCaspase 8 inhibits programmed necrosis by processing CYLDA non-canonical role of the p97 complex in RIG-I antiviral signalingInduction of type I interferon by RNA viruses: cellular receptors and their substratesCasein kinase II controls TBK1/IRF3 activation in IFN response against viral infection.TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinomaToll-like receptor-mediated down-regulation of the deubiquitinase cylindromatosis (CYLD) protects macrophages from necroptosis in wild-derived miceRegulation of virus-triggered signaling by OTUB1- and OTUB2-mediated deubiquitination of TRAF3 and TRAF6.TAX1BP1 and A20 inhibit antiviral signaling by targeting TBK1-IKKi kinasesCoronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signalingA20 (Tnfaip3) deficiency in myeloid cells protects against influenza A virus infection.Downregulation of microRNA miR-526a by enterovirus inhibits RIG-I-dependent innate immune response.NEMO binds ubiquitinated TANK-binding kinase 1 (TBK1) to regulate innate immune responses to RNA viruses.The ubiquitin E3 ligase RAUL negatively regulates type i interferon through ubiquitination of the transcription factors IRF7 and IRF3.RING finger protein 11 targets TBK1/IKKi kinases to inhibit antiviral signaling.CYLD regulates RhoA activity by modulating LARG ubiquitination.
P2860
0afa72e820439a85a5f3a77c972a7a6f7db5fb9d4262c8dbbb8a3b42d020b8ca87dc0a6919dde56c65d04e9f1272cedfdf3accbbe22addb6b2c78e327b6ba502f2838b3dada4bf3fed3376d17f28ab30891fda78d133e7897c50f2b9dfb1959bbc05053ea8c07172b3a8eb7ff9292645fc9af9e7aaa5a293b595df4a30623022e8996b36a8a4500fd33c794ad34b733c63346d67e2c7344f2cf0838ea3bcf540eb22da7a4f86c46abe0abd630bca3e2778e759e9f05623ea8c6b2ac017d8242ae42abdd20dfdcd49
P248
Q24298547-0C07EC2D-FF75-4362-9F0E-38BF1A558D06Q24300481-64243119-AB8C-4CA7-ADB7-2A1A041EC24AQ24304438-E41B901E-EB18-421F-AD0D-A3DFD1D5B999Q24305205-E1613916-7815-4D30-BD13-CFC1CA279DCBQ24306232-BAB4F2C7-F97D-4696-8BD7-741C3C102205Q24307162-AF4CA9CC-3B8F-4114-9C35-0803441EBF33Q24307928-C4FDAAEF-B410-4F70-897B-3EF4146839A2Q24311676-AD324D70-1324-4863-A241-3E13849C64B8Q24315750-B6F689D4-68FD-4DA7-BF5E-91098D715776Q24316163-28863A8E-8401-43E2-AEEB-2D111F17EB85Q24316185-45819913-652D-4123-B4B4-6553898727CDQ24337463-BC398FB2-A38C-4D75-AFB1-C788000A12F3Q24632537-A10CAF0D-57E7-4C36-9097-6B26CE8FFC6BQ26751376-63CA3861-3AAD-428D-890D-068876E953EAQ26771789-A0A21798-D83C-4022-AED7-6F984898B1A0Q26853682-EE97C23C-0F7D-4BE7-B126-B3A9EF290DB3Q26998711-A82F95DC-D7B5-4B95-AFDA-6ACC9580D842Q27487296-CB93F37D-79D9-471E-9F27-4472B96245D2Q27674485-A51B0E8B-6892-45E9-A67C-D0C353363424Q28081647-5FB3A137-8FD4-45C9-91CF-C5B6294640DBQ28084011-C18B8A82-C8F1-45C8-9832-D3A415571F98Q28116012-BFE9C35B-0BD7-4049-B7B2-1333460FF586Q28262399-94AD7A5F-8A81-4DFD-9103-96FFEACC385DQ28478468-230333DB-EDDA-48B4-901B-D5AFE082FFD6Q28507375-4EE31AEB-18CB-40CA-A536-CD44E07B13E1Q28584927-9599C8A0-1291-46BE-B763-4252A1BD74BEQ28596603-4ACEA987-43AA-490A-AD5D-828BF67890B6Q29042349-4C0A9D16-4982-493A-9AEE-C0A4BB53C2A0Q30373058-8C8F884A-CE3E-4A8B-B061-164AFA94CA82Q30491128-00DFCD97-25C0-419E-97E0-80AA7FB08CD0Q33619601-6AF488AC-2E75-4A08-B79D-D7754D343CD0Q33717393-5E82C5A4-4502-4924-82FA-7AE6432A500DQ33832484-0E91CDA3-6B28-4B7D-9DF3-876696BEA1C4Q34152661-ECE12479-886C-4D92-83D4-367DE225F9C1Q34187000-AE2E22A6-2093-469A-8258-CEB9F2A56CA3Q34261757-066F2179-9AD9-4D91-A9C4-0395793EAEBFQ34426832-6C9D8C3A-A5E5-4033-9F26-E57D4A650CD7Q34449547-AFCA991B-B604-46BE-B13E-C12232483DDDQ34545358-69D57CB3-EAC9-4CB2-ADB9-98736CFCD0AAQ34584522-66476B95-ABBF-44C5-9208-974D5F5420B1
P2860
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response
@ast
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response
@en
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response
@en-gb
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response
@nl
type
label
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response
@ast
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response
@en
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response
@en-gb
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response
@nl
prefLabel
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response
@ast
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response
@en
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response
@en-gb
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response
@nl
P2093
P2860
P3181
P356
P1433
P1476
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response
@en
P2093
Adrian T Ting
Akihiko Komuro
Christopher F Basler
Constantin S Friedman
Curt M Horvath
Diana Legarda-Addison
Jacob S Yount
Marie Anne O'Donnell
Ramnik Xavier
P2860
P3181
P356
10.1038/EMBOR.2008.136
P407
P577
2008-09-01T00:00:00Z